Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 30 adults (53 to 86) with type 2 diabetes and moderate painful peripheral neuropathy at one health centre in Sicily; 29 completed
- Dose used in the study
- Micronised PEA (Normast) 300 mg twice daily
- Duration
- 60 days, with a follow-up visit at 90 days
- What was measured
- Michigan Neuropathy Screening Instrument, Total Symptom Score and Neuropathic Pain Symptom Inventory at 0, 30 and 60 days; blood and urine tests
What the authors reported
All three scores fell by day 30 and further by day 60 (p < 0.0001), across pain, burning, paraesthesia and numbness. Most of the effect remained one month after stopping. No changes in blood tests; one patient stopped for sleepiness.
Limits of this study
Open label, no control group; the authors say so. 30 patients. Usual medicines continued. Effect sizes are shown in figures only. Product is Epitech's Normast.
Source
PubMed 24804094 · doi:10.1155/2014/849623
Entry checked against the full text, supplied by Devlin on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.